PE20200610A1 - Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales - Google Patents

Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales

Info

Publication number
PE20200610A1
PE20200610A1 PE2019002493A PE2019002493A PE20200610A1 PE 20200610 A1 PE20200610 A1 PE 20200610A1 PE 2019002493 A PE2019002493 A PE 2019002493A PE 2019002493 A PE2019002493 A PE 2019002493A PE 20200610 A1 PE20200610 A1 PE 20200610A1
Authority
PE
Peru
Prior art keywords
seq
isvd
cdr1
cdr2
cdr3
Prior art date
Application number
PE2019002493A
Other languages
English (en)
Inventor
Vittoria Zinzalla
Klaus Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200610(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20200610A1 publication Critical patent/PE20200610A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Referido a un polipeptido que se fija a la proteina 5 de tipo receptor de lipoproteinas de baja densidad (LRP5), que comprende un dominio variable unico de inmunoglobulina (ISVD) seleccionado del grupo de: (i) un ISVD que comprende las siguientes secuencia de regiones determinantes de la complementariedad : CDR1:TYVMG (SEQ ID NO:1), CDR2: AISWSGGSTYYADSVKG (SEQ ID NO:2), CDR3: SRGTSTPSRASGVSRYDY (SEQ ID NO:3), (ii) un ISVD que comprende las secuencias: CDR1: RYAVA (SEQ ID NO:4), CDR2: AITWSSGRIDYADSVKG (SEQ ID NO:5), CDR3: DRRPRSTGRSGTGSPSTYDY (SEQ ID NO:6); (iii) un ISVD que comprende: CDR1: IGAMG (SEQ ID NO:7), CDR2: AVSSGGSTYYVDSVKG (SEQ ID NO:8), CDR3: ETGPYGPPKRDY (SEQ ID NO:9) y (iv) un ISVD que comprende: CDR1:INAMG (SEQ ID NO:10), CDR2: AVSSGGSTYYVDSVKG (SEQ ID NO:8), CDR3: ETGPYGPPKRDY (SEQ ID NO:9). Dicho polipeptido inhibe la via de senalizacion Wnt1/Wnt3a siendo util en el tratamiento del cancer de mama, cancer de pulmon, entre otros. Tambien se refiere a una molecula de acido nucleico que codifica el polipeptido, un vector de expresion, una celula huesped una composicion farmaceutica que comprende dicho polipeptido, un metodo de produccion y a un metodo de tratamiento.
PE2019002493A 2017-05-31 2018-05-30 Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales PE20200610A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31
PCT/EP2018/064295 WO2018220080A1 (en) 2017-05-31 2018-05-30 Polypeptides antagonizing wnt signaling in tumor cells

Publications (1)

Publication Number Publication Date
PE20200610A1 true PE20200610A1 (es) 2020-03-10

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002493A PE20200610A1 (es) 2017-05-31 2018-05-30 Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales

Country Status (26)

Country Link
US (3) US11033636B2 (es)
EP (1) EP3630816B1 (es)
JP (1) JP7216024B2 (es)
KR (1) KR102717656B1 (es)
CN (1) CN110637030B (es)
AR (1) AR111840A1 (es)
AU (1) AU2018276409B2 (es)
BR (1) BR112019022729A2 (es)
CA (1) CA3060401A1 (es)
CL (1) CL2019003419A1 (es)
CO (1) CO2019012329A2 (es)
EA (1) EA201992808A1 (es)
ES (1) ES2979194T3 (es)
HU (1) HUE067691T2 (es)
IL (1) IL270854B2 (es)
MA (1) MA48760A (es)
MX (1) MX2019014331A (es)
MY (1) MY200744A (es)
NZ (1) NZ758031A (es)
PE (1) PE20200610A1 (es)
PH (1) PH12019502602A1 (es)
PL (1) PL3630816T3 (es)
TW (1) TWI887192B (es)
UA (1) UA125761C2 (es)
WO (1) WO2018220080A1 (es)
ZA (1) ZA201906610B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法
JP7840842B2 (ja) * 2019-08-14 2026-04-06 アントレラ セラピューティクス インコーポレイテッド Ｌｒｐ５タンパク質に結合する抗体および使用方法
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
KR102920873B1 (ko) * 2021-07-13 2026-02-02 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
WO2023019137A1 (en) * 2021-08-10 2023-02-16 Heat Biologics, Inc. Generation and characterization of novel tim-4 binding agents
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69837542T2 (de) 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CA2825211A1 (en) * 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Standford Junior University Wnt compositions and methods of use thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
US9200072B2 (en) 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法

Also Published As

Publication number Publication date
US20180344868A1 (en) 2018-12-06
CN110637030B (zh) 2024-06-11
IL270854B (en) 2022-10-01
BR112019022729A2 (pt) 2020-05-19
UA125761C2 (uk) 2022-06-01
WO2018220080A1 (en) 2018-12-06
JP7216024B2 (ja) 2023-01-31
CL2019003419A1 (es) 2020-03-27
AU2018276409B2 (en) 2025-02-27
US11033636B2 (en) 2021-06-15
US20220362393A1 (en) 2022-11-17
PH12019502602A1 (en) 2020-06-08
KR20200011933A (ko) 2020-02-04
ES2979194T3 (es) 2024-09-24
HUE067691T2 (hu) 2024-11-28
AU2018276409A1 (en) 2019-10-31
US12285493B2 (en) 2025-04-29
MY200744A (en) 2024-01-13
NZ758031A (en) 2026-03-27
CO2019012329A2 (es) 2020-01-17
ZA201906610B (en) 2025-12-17
AR111840A1 (es) 2019-08-21
KR102717656B1 (ko) 2024-10-14
CA3060401A1 (en) 2018-12-06
JP2020521478A (ja) 2020-07-27
TWI887192B (zh) 2025-06-21
PL3630816T3 (pl) 2024-08-05
MX2019014331A (es) 2020-01-27
IL270854A (en) 2020-01-30
EP3630816B1 (en) 2024-03-20
US20250345448A1 (en) 2025-11-13
EP3630816A1 (en) 2020-04-08
IL270854B2 (en) 2023-02-01
EA201992808A1 (ru) 2020-05-14
TW201906858A (zh) 2019-02-16
EP3630816C0 (en) 2024-03-20
MA48760A (fr) 2020-04-08
CN110637030A (zh) 2019-12-31

Similar Documents

Publication Publication Date Title
PE20200610A1 (es) Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
AR106949A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20190976A1 (es) Anticuerpos de union a cd3
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
CO2019006657A2 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20180481A1 (es) Anticuerpos de union a tau
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
EA202091710A1 (ru) Антитела против cd73 и способы их применения
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
PE20180120A1 (es) Proteinas de union a icos
PE20181517A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
AR087615A1 (es) Moleculas biespecificas de union a antigeno
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
AR105724A1 (es) Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
PE20121184A1 (es) Moleculas de union a dll-4
EA202090275A3 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
PE20181956A1 (es) Polipeptidos que inhiben cd40l